KR102708321B1 - 홍합 접착 단백질 제품, 및 점막 염증을 억제하기 위한 그것의 용도 - Google Patents
홍합 접착 단백질 제품, 및 점막 염증을 억제하기 위한 그것의 용도 Download PDFInfo
- Publication number
- KR102708321B1 KR102708321B1 KR1020187003844A KR20187003844A KR102708321B1 KR 102708321 B1 KR102708321 B1 KR 102708321B1 KR 1020187003844 A KR1020187003844 A KR 1020187003844A KR 20187003844 A KR20187003844 A KR 20187003844A KR 102708321 B1 KR102708321 B1 KR 102708321B1
- Authority
- KR
- South Korea
- Prior art keywords
- map
- cancer
- patients
- treatment
- mefp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003988 mussel adhesive protein Substances 0.000 title claims abstract description 379
- 108010004563 mussel adhesive protein Proteins 0.000 title claims abstract description 379
- 206010028116 Mucosal inflammation Diseases 0.000 title abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 115
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 230000004054 inflammatory process Effects 0.000 claims abstract description 54
- 206010061218 Inflammation Diseases 0.000 claims abstract description 53
- 238000009472 formulation Methods 0.000 claims abstract description 53
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 41
- 230000036541 health Effects 0.000 claims abstract description 41
- 206010039083 rhinitis Diseases 0.000 claims abstract description 40
- 208000007882 Gastritis Diseases 0.000 claims abstract description 38
- 201000008197 Laryngitis Diseases 0.000 claims abstract description 37
- 206010044302 Tracheitis Diseases 0.000 claims abstract description 33
- 208000003265 stomatitis Diseases 0.000 claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000006260 foam Substances 0.000 claims description 83
- 239000012669 liquid formulation Substances 0.000 claims description 18
- 239000000645 desinfectant Substances 0.000 claims description 16
- 210000004877 mucosa Anatomy 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 6
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 208000010227 enterocolitis Diseases 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 239000000668 oral spray Substances 0.000 claims 1
- 229940041678 oral spray Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 112
- 208000002193 Pain Diseases 0.000 abstract description 44
- 206010010741 Conjunctivitis Diseases 0.000 abstract description 39
- 208000004145 Endometritis Diseases 0.000 abstract description 35
- 208000006374 Uterine Cervicitis Diseases 0.000 abstract description 30
- 206010008323 cervicitis Diseases 0.000 abstract description 30
- 230000006378 damage Effects 0.000 abstract description 30
- 206010030216 Oesophagitis Diseases 0.000 abstract description 28
- 206010033078 Otitis media Diseases 0.000 abstract description 28
- 208000006881 esophagitis Diseases 0.000 abstract description 28
- 208000004232 Enteritis Diseases 0.000 abstract description 25
- 208000027418 Wounds and injury Diseases 0.000 abstract description 25
- 208000014674 injury Diseases 0.000 abstract description 25
- 208000003251 Pruritus Diseases 0.000 abstract description 19
- 230000007803 itching Effects 0.000 abstract description 19
- 239000003845 household chemical Substances 0.000 abstract description 18
- 230000000249 desinfective effect Effects 0.000 abstract description 11
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 10
- 206010014733 Endometrial cancer Diseases 0.000 abstract description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 10
- 206010023825 Laryngeal cancer Diseases 0.000 abstract description 10
- 208000003445 Mouth Neoplasms Diseases 0.000 abstract description 10
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract description 10
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 10
- 201000010881 cervical cancer Diseases 0.000 abstract description 10
- 201000000787 conjunctival cancer Diseases 0.000 abstract description 10
- 201000004101 esophageal cancer Diseases 0.000 abstract description 10
- 206010017758 gastric cancer Diseases 0.000 abstract description 10
- 201000002313 intestinal cancer Diseases 0.000 abstract description 10
- 206010023841 laryngeal neoplasm Diseases 0.000 abstract description 10
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 abstract description 10
- 201000003956 middle ear cancer Diseases 0.000 abstract description 10
- 201000011549 stomach cancer Diseases 0.000 abstract description 10
- 206010044285 tracheal cancer Diseases 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 9
- 230000008961 swelling Effects 0.000 abstract description 5
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 4
- 206010037660 Pyrexia Diseases 0.000 abstract description 2
- 229940127554 medical product Drugs 0.000 abstract description 2
- 206010015150 Erythema Diseases 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 89
- 239000000499 gel Substances 0.000 description 81
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 56
- 239000007788 liquid Substances 0.000 description 52
- 208000025865 Ulcer Diseases 0.000 description 45
- 231100000397 ulcer Toxicity 0.000 description 45
- 238000012360 testing method Methods 0.000 description 39
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 36
- 238000005507 spraying Methods 0.000 description 32
- 239000011159 matrix material Substances 0.000 description 25
- 208000027744 congestion Diseases 0.000 description 20
- 230000002496 gastric effect Effects 0.000 description 19
- 230000007794 irritation Effects 0.000 description 19
- 238000013268 sustained release Methods 0.000 description 19
- 239000012730 sustained-release form Substances 0.000 description 19
- 241000237536 Mytilus edulis Species 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 230000001154 acute effect Effects 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 235000020638 mussel Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 12
- 208000012876 acute enteritis Diseases 0.000 description 12
- 210000003679 cervix uteri Anatomy 0.000 description 12
- 210000001331 nose Anatomy 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 239000000017 hydrogel Substances 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 11
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 10
- 206010036790 Productive cough Diseases 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000024794 sputum Diseases 0.000 description 10
- 210000003802 sputum Anatomy 0.000 description 10
- 206010006784 Burning sensation Diseases 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 206010039101 Rhinorrhoea Diseases 0.000 description 9
- 208000033809 Suppuration Diseases 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 210000003756 cervix mucus Anatomy 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 238000001839 endoscopy Methods 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 230000002035 prolonged effect Effects 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 235000019615 sensations Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000002485 urinary effect Effects 0.000 description 9
- 206010046901 vaginal discharge Diseases 0.000 description 9
- 206010028735 Nasal congestion Diseases 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 206010007134 Candida infections Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 229920001214 Polysorbate 60 Polymers 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 206010013789 Dry throat Diseases 0.000 description 6
- 206010014020 Ear pain Diseases 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 6
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 208000007176 earache Diseases 0.000 description 6
- 230000003628 erosive effect Effects 0.000 description 6
- 201000005917 gastric ulcer Diseases 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000002262 irrigation Effects 0.000 description 6
- 238000003973 irrigation Methods 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 230000008693 nausea Effects 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004088 foaming agent Substances 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 208000010753 nasal discharge Diseases 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229920002907 Guar gum Polymers 0.000 description 4
- 206010065334 Mucosal hyperaemia Diseases 0.000 description 4
- 208000036071 Rhinorrhea Diseases 0.000 description 4
- 201000010550 acute laryngitis Diseases 0.000 description 4
- 208000016150 acute pharyngitis Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 235000010417 guar gum Nutrition 0.000 description 4
- 239000000665 guar gum Substances 0.000 description 4
- 229960002154 guar gum Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- ZSAZGCBSZUURAX-UHFFFAOYSA-N 1-chloro-4-(diethoxyphosphorylsulfanylmethylsulfanyl)benzene Chemical compound CCOP(=O)(OCC)SCSC1=CC=C(Cl)C=C1 ZSAZGCBSZUURAX-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 108060003393 Granulin Proteins 0.000 description 3
- 101000574396 Homo sapiens Protein phosphatase 1K, mitochondrial Proteins 0.000 description 3
- 208000007027 Oral Candidiasis Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 102100025799 Protein phosphatase 1K, mitochondrial Human genes 0.000 description 3
- 201000002014 Suppurative Otitis Media Diseases 0.000 description 3
- 241000287411 Turdidae Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 3
- 210000000959 ear middle Anatomy 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 229940100573 methylpropanediol Drugs 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004876 tela submucosa Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 241001072261 Musculista senhousia Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000009448 modified atmosphere packaging Methods 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108010029240 Cell-Tak Proteins 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- RZXLPPRPEOUENN-UHFFFAOYSA-N Chlorfenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=C(Cl)C=C1 RZXLPPRPEOUENN-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010070814 Corrosive gastritis Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057869 Pharyngitis bacterial Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037569 Purulent discharge Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010043991 Tongue ulceration Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000004171 acute endometritis Diseases 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000006766 bile reflux Diseases 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000030373 chronic endometritis Diseases 0.000 description 1
- 208000015864 chronic erosive gastritis Diseases 0.000 description 1
- 201000007024 chronic follicular conjunctivitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000009243 chronic laryngitis Diseases 0.000 description 1
- 239000003653 coastal water Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000001033 conjunctival folliculosis Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004393 laryngeal mucosa Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- -1 medical devices Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 201000004421 pseudomembranous conjunctivitis Diseases 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/087011 WO2017028025A1 (zh) | 2015-08-14 | 2015-08-14 | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 |
| CNPCT/CN2015/087011 | 2015-08-14 | ||
| PCT/CN2016/095364 WO2017028777A1 (zh) | 2015-08-14 | 2016-08-15 | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180033517A KR20180033517A (ko) | 2018-04-03 |
| KR102708321B1 true KR102708321B1 (ko) | 2024-09-23 |
Family
ID=58050454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187003844A Active KR102708321B1 (ko) | 2015-08-14 | 2016-08-15 | 홍합 접착 단백질 제품, 및 점막 염증을 억제하기 위한 그것의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10485848B2 (enExample) |
| EP (1) | EP3335739B1 (enExample) |
| JP (1) | JP6816098B2 (enExample) |
| KR (1) | KR102708321B1 (enExample) |
| CN (1) | CN108348636B (enExample) |
| AU (1) | AU2016309397B2 (enExample) |
| CA (1) | CA2995549C (enExample) |
| DK (1) | DK3335739T3 (enExample) |
| MA (1) | MA42629A (enExample) |
| MX (1) | MX2018000654A (enExample) |
| SG (1) | SG11201800578YA (enExample) |
| WO (2) | WO2017028025A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018000953A2 (pt) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele |
| KR102468524B1 (ko) | 2015-07-20 | 2022-11-18 | 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 | 멜라닌과 관련된 질환의 치료 및 예방에서의 홍합 접착 단백질 제품의 용도 |
| WO2017011986A1 (zh) | 2015-07-20 | 2017-01-26 | 赵兵 | 一种空气过滤装置 |
| WO2017028025A1 (zh) | 2015-08-14 | 2017-02-23 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 |
| CN110139662B (zh) * | 2017-07-05 | 2022-03-18 | 江阴贝瑞森制药有限公司 | 肽的抗炎用途 |
| MA52794A (fr) * | 2018-05-28 | 2021-04-14 | Jiangyin Usun Pharmaceutical Co Ltd | Nouvelle utilisation pharmaceutique |
| KR102787480B1 (ko) * | 2019-03-12 | 2025-03-28 | 항저우 잉지엔 바이오테크놀로지 컴퍼니 리미티드 | 소화관 점막 보호 겔 |
| EP4028409A4 (en) * | 2019-09-14 | 2023-10-11 | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | NEW PEPTIDES |
| US20240218016A1 (en) * | 2019-12-02 | 2024-07-04 | Shenzhen Institutes Of Advanced Technology | Peptides and their use in the treatment of inflammation |
| KR102596264B1 (ko) | 2020-11-30 | 2023-11-01 | 주식회사 바이오빛 | 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물 |
| CN114588267A (zh) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | 一种含酰胺类局部麻醉药的药物组合物 |
| CN112695064B (zh) * | 2021-02-01 | 2023-06-16 | 大连海洋大学 | 从海洋腹足类黏液中提取的抗肝癌和抗肝纤维化的低聚肽 |
| JP2022172889A (ja) * | 2021-05-07 | 2022-11-17 | 大和製罐株式会社 | 吐出容器入り薬液 |
| CN115778926A (zh) * | 2023-01-30 | 2023-03-14 | 南京天纵易康生物科技股份有限公司 | 一种含贻贝粘蛋白的可降解唇部护理贴剂及其制备方法 |
| CN118059215B (zh) * | 2024-01-23 | 2024-08-30 | 海南美安生物医药科技有限公司 | 一种妇科温敏型原位凝胶及其制备和应用 |
| WO2025195444A1 (en) | 2024-03-20 | 2025-09-25 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New use of peptides derived from vasoactive intestinal peptide |
| CN118236471B (zh) * | 2024-03-21 | 2025-08-19 | 湖南天根乐微君科技有限公司 | 一种用于改善鼻炎症状和鼻腔清洗的组合物及其制备方法和应用 |
| CN120189380B (zh) * | 2025-03-21 | 2026-03-31 | 大连医科大学 | 黏蛋白温敏水凝胶的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186937A1 (zh) * | 2013-05-20 | 2014-11-27 | Gao Min | 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| RU2043109C1 (ru) | 1992-03-17 | 1995-09-10 | Маина Александровна Бичурина | Способ ингибиции вируса гриппа серотипов а и в |
| CN1112831A (zh) | 1994-05-30 | 1995-12-06 | 乌力吉 | 含蜗牛提取液的长效多功能营养护肤水及其制法 |
| NZ314867A (en) * | 1997-05-21 | 1999-04-29 | Mcfarlane Lab New Zealand Ltd | Glucosamine and mussel extract compositions for use as anti-inflammatories |
| AU767122B2 (en) | 1998-06-10 | 2003-10-30 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
| US20020018787A1 (en) | 1999-05-21 | 2002-02-14 | Roger V. Kendall | Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| DE60038320D1 (de) | 1999-07-21 | 2008-04-24 | Bomac Research Ltd | Mittel zur bekämpfung von entzündungen und/oder degenerativen erkrankungen |
| EP1217985A4 (en) | 1999-08-16 | 2003-07-30 | Playtex Products Inc | SUN PROTECTION AGENT IN THE FORM OF A LOTION OR SPRAY |
| US6770302B2 (en) | 2001-03-30 | 2004-08-03 | Department Of Biotechnology | Indian green mussel (Perna viridis) as a source of anti-HIV activity |
| US7074433B2 (en) | 2001-03-30 | 2006-07-11 | Council Of Scientific And Industrial Research | Process for the cure and control of Diabetes mellitus using natural products from Perna viridis |
| US6905710B2 (en) | 2001-08-31 | 2005-06-14 | Council Of Scientific And Industrial Research | Pharmaceutical composition useful for inhibition of osteoclast formation and a process for the extraction of mussel hudrolysate from indian green mussel |
| US20060275370A1 (en) * | 2002-07-25 | 2006-12-07 | Yih-Lin Chung | Method and compositions for treatment of epithelial damage |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| AU2004314731B2 (en) * | 2004-01-20 | 2011-07-07 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| CN101348518B (zh) | 2007-12-14 | 2011-09-28 | 顾铭 | 一种使用羧甲基离子交换色谱纯化贻贝粘蛋白的方法 |
| CN101348520B (zh) | 2007-12-14 | 2011-10-12 | 顾铭 | 一种使用混合吸附色谱分离纯化贻贝粘蛋白的方法 |
| KR101022884B1 (ko) * | 2009-06-12 | 2011-03-16 | 주식회사 원바이오젠 | 약물층을 포함하는 폴리우레탄 폼 드레싱제 및 그 제조방법 |
| CN101585874B (zh) | 2009-06-30 | 2012-08-22 | 江阴贝瑞森生化技术有限公司 | 一种使用盐析和透析分离纯化贻贝粘蛋白的方法 |
| JP2012526155A (ja) | 2009-08-25 | 2012-10-25 | ポステック アカデミー−インダストリー ファンデーション | イガイ接着蛋白質またはその変異体に陰イオン性高分子が含まれたコアセルベート |
| KR101147847B1 (ko) | 2010-06-02 | 2012-05-24 | 건국대학교 산학협력단 | 패류 유래 기능성 펩티드의 분리 정제 방법 및 기능성 펩티드의 용도 |
| CN101991840B (zh) | 2010-09-26 | 2012-09-05 | 浙江海洋学院 | 抗前列腺癌贻贝酶解提取物的制备方法及应用 |
| KR101384746B1 (ko) | 2011-08-24 | 2014-04-14 | 포항공과대학교 산학협력단 | 홍합 접착 단백질을 이용한 다양한 기능성 생체분자의 표면 고정화 |
| CN102302417B (zh) | 2011-09-13 | 2012-12-26 | 佛山市安安美容保健品有限公司 | 一种含有海洋生物活性物质的全效防晒乳液 |
| WO2013143077A1 (zh) * | 2012-03-28 | 2013-10-03 | 江阴贝瑞森生化技术有限公司 | 使用多模式色谱纯化贻贝粘蛋白的方法 |
| CN103520766A (zh) * | 2013-09-25 | 2014-01-22 | 高敏 | 贻贝粘蛋白液体产品、其制备方法及其应用 |
| CN104323927A (zh) | 2014-11-06 | 2015-02-04 | 济南星河康泰贸易有限公司 | 贻贝粘蛋白在制备皮肤美容化妆品上的应用 |
| CN104645313A (zh) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | 一种修复止痒贻贝粘蛋白凝胶剂及其制备方法 |
| CN104645320A (zh) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | 一种创面修复用贻贝粘蛋白凝胶剂及其制备方法和应用 |
| CN104857552B (zh) | 2015-05-18 | 2018-08-10 | 赵明 | 一种止血贴及其制备方法 |
| BR112018000953A2 (pt) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele |
| KR102468524B1 (ko) | 2015-07-20 | 2022-11-18 | 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 | 멜라닌과 관련된 질환의 치료 및 예방에서의 홍합 접착 단백질 제품의 용도 |
| WO2017011986A1 (zh) | 2015-07-20 | 2017-01-26 | 赵兵 | 一种空气过滤装置 |
| WO2017028025A1 (zh) | 2015-08-14 | 2017-02-23 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 |
-
2015
- 2015-08-14 WO PCT/CN2015/087011 patent/WO2017028025A1/zh not_active Ceased
-
2016
- 2016-08-15 MA MA042629A patent/MA42629A/fr unknown
- 2016-08-15 KR KR1020187003844A patent/KR102708321B1/ko active Active
- 2016-08-15 AU AU2016309397A patent/AU2016309397B2/en active Active
- 2016-08-15 EP EP16836641.7A patent/EP3335739B1/en active Active
- 2016-08-15 DK DK16836641.7T patent/DK3335739T3/da active
- 2016-08-15 SG SG11201800578YA patent/SG11201800578YA/en unknown
- 2016-08-15 JP JP2018501271A patent/JP6816098B2/ja active Active
- 2016-08-15 US US15/751,551 patent/US10485848B2/en active Active
- 2016-08-15 CN CN201680041312.4A patent/CN108348636B/zh active Active
- 2016-08-15 MX MX2018000654A patent/MX2018000654A/es unknown
- 2016-08-15 CA CA2995549A patent/CA2995549C/en active Active
- 2016-08-15 WO PCT/CN2016/095364 patent/WO2017028777A1/zh not_active Ceased
-
2019
- 2019-10-01 US US16/589,346 patent/US11458190B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186937A1 (zh) * | 2013-05-20 | 2014-11-27 | Gao Min | 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| 연합뉴스기사 ‘홍합접착단백질 기반 생체접착물질 개발’ (2010.3.14)* |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016309397A1 (en) | 2018-03-01 |
| SG11201800578YA (en) | 2018-02-27 |
| CA2995549A1 (en) | 2017-02-23 |
| AU2016309397B2 (en) | 2020-10-22 |
| JP2019501108A (ja) | 2019-01-17 |
| HK1257176A1 (en) | 2019-10-18 |
| EP3335739A1 (en) | 2018-06-20 |
| MX2018000654A (es) | 2018-07-06 |
| KR20180033517A (ko) | 2018-04-03 |
| US11458190B2 (en) | 2022-10-04 |
| CA2995549C (en) | 2024-01-02 |
| US20180243371A1 (en) | 2018-08-30 |
| US20200101135A1 (en) | 2020-04-02 |
| MA42629A (fr) | 2018-06-20 |
| CN108348636A (zh) | 2018-07-31 |
| JP6816098B2 (ja) | 2021-01-20 |
| US10485848B2 (en) | 2019-11-26 |
| EP3335739A4 (en) | 2019-04-03 |
| DK3335739T3 (en) | 2023-11-13 |
| CN108348636B (zh) | 2021-05-25 |
| WO2017028025A1 (zh) | 2017-02-23 |
| EP3335739B1 (en) | 2023-10-04 |
| WO2017028777A1 (zh) | 2017-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11458190B2 (en) | Mussel adhesive protein product and use thereof for treating mucosal inflammation | |
| CN108348577B (zh) | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 | |
| CN105148253B (zh) | 皮肤黏膜抗菌组合物 | |
| RU2403012C2 (ru) | Мукоадгезивные ксилоглюкансодержащие препараты, полезные в медицинских устройствах и в фармацевтических препаратах | |
| US20160220722A1 (en) | Wound Healing Compositions Involving Medicinal Honey, Mineral ions, and Methylglyoxal, and Methods of Use | |
| JPH04500798A (ja) | 硫酸化糖類の用途 | |
| EA011298B1 (ru) | Применение бактерицидных пиримидинов для профилактики передачи вич половым путём и фармацевтические композиции на их основе | |
| JP2016056186A (ja) | 抗菌剤およびその使用法 | |
| CN106466454A (zh) | 一种预防及治疗妇科炎症的凝胶剂 | |
| JP3103373B2 (ja) | ククイナット外皮由来の抗ウイルス剤 | |
| HK1257176B (en) | Mussel adhesive protein product and the use thereof for the treatment of inflammation of the mucosa | |
| RU2173155C1 (ru) | Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат | |
| RU2221562C1 (ru) | Лекарственное средство и способ лечения генитального остроконечного кондиломатоза | |
| US20140301954A1 (en) | Mucous membrane active agent application | |
| CN112546232A (zh) | 一种用于预防幽门螺杆菌感染的制剂 | |
| US8492443B2 (en) | Treatment for herpes simplex virus and other infectious diseases | |
| WO2017028775A1 (zh) | 贻贝粘蛋白用于粘膜的防护 | |
| JP2019521134A (ja) | 性感染症用組成物 | |
| JP2006516964A (ja) | 三つ葉型ドメイン含有ポリペプチドおよびその使用 | |
| CN103520707A (zh) | 一种益菌治菌预防和治疗生殖系统感染的组合物 | |
| CA2591352A1 (en) | Treatment for herpes simplex virus and other infectious diseases | |
| CN110859875A (zh) | 一种苯妥英银复方药物及使用其制备的外用制剂 | |
| CN106692952A (zh) | 一种治疗肛门瘙痒和皲裂的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180208 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210802 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240110 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240613 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240913 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240919 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |